Pentobarbital will decrease the level or effect of fentanyl transdermal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with CYP3A4 inducers could lead to a decrease Per fentanyl plasma concentrations, lack of efficacy or, possibly, development of a withdrawal syndrome Sopra a patient who has developed https://pentobarbitalapotheekonli71481.blog-mall.com/36824055/pentobarbital-nederland-winkel-grondslagen-uitgelegd